Double Bond Pharmaceutical International AB is a pharmaceutical company, which engages in developing and commercializing approaches for treatment of cancers, infections, autoimmune diseases, and life-threatening disorders. It also involves in designing medicinal products for patients suffering from diseases such as cancer, inflammation, asthma or diabetes. The company was founded on November 21, 2014 and is headquartered in Uppsala, Sweden.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company